InCarda Therapeutics Elects Dr. Norbert Bischofberger to Board of Directors
San Francisco, California, June 7, 2016 – InCarda Therapeutics, Inc. (InCarda), a privately-held biopharmaceutical company focused on the development of therapies for cardiovascular conditions via the inhalation route, today announced the election of Norbert Bischofberger, Ph.D., to the company’s board of directors. Dr. Bischofberger has spent over 25 years at Gilead Sciences, where he currently serves as the company’s chief scientific officer and executive vice president of research and development.
“Dr. Bischofberger has been a key driver of Gilead’s success, and we’re very pleased to have his unique acumen and insights advising InCarda on product and pipeline development,” said Grace E. Colon, Ph.D., President and Chief Executive Officer of InCarda Therapeutics. “We are deeply honored to have him join our Board and help guide InCarda as a developer of paradigm-shifting therapies for cardiovascular conditions.”
“InCarda has an exciting therapy for atrial fibrillation and a novel approach that I believe has potential to significantly improve the treatment of acute cardiac conditions. I look forward to contributing to the development of important medications by this promising company,” stated Dr. Bischofberger.
Dr. Norbert Bischofberger has served at Gilead Sciences since 1990 and is currently the company’s chief scientific officer and executive vice president of research and development. He is one of the inventors of the company’s successful antiviral drug, Tamiflu. Prior to joining Gilead, Dr. Bischofberger served in Genentech’s DNA Synthesis Group from 1986 to 1990. He received his Ph.D. in organic chemistry from Zurich’s Eidgenossische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also served in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts where he performed research in organic chemistry and enzymology.
About InCarda (www.incardatherapeutics.com)
InCarda Therapeutics, located in the San Francisco Bay Area with operations in Australia, is focused on transforming cardiovascular disease treatment through pulmonary delivery of established drugs. The company is product-focused with significant inhalation delivery capabilities and led by a team with extensive experience in cardiovascular drug development. The lead product under development is an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF). InCarda is also working on additional research concepts that leverage the same approach to target the heart for acute cardiac conditions. The company’s approach is designed to reduce the risk normally associated with drug development. InCarda’s model is based on the following three tenets: known diseases, known drugs, new delivery.